Key result
Circulating microRNAs are emerging as potential biomarkers to improve risk stratification and predict the progression of aortic disease in patients with bicuspid aortic valve aortopathy.
Why the study?
Diameter-based risk stratification for adverse aortic events in bicuspid aortic valve aortopathy has inherent limitations, creating an urgent need for alternative diagnostic tools and guideline adjustments.
Do circulating microRNAs improve risk stratification for adverse aortic events compared to diameter-based assessment in patients with bicuspid aortic valve aortopathy?
Do circulating microRNAs improve risk stratification for adverse aortic events compared to diameter-based assessment in patients with bicuspid aortic valve aortopathy?
Circulating microRNAs represent a promising alternative or adjunct to diameter-based risk stratification for predicting adverse aortic events in bicuspid aortic valve aortopathy.
Answers are grounded in this paper and cite their sources.
MicroRNA biomarkers may aid risk stratification in bicuspid aortopathy; leaves open validation against diameter criteria in prospective cohorts.
There is growing clinical need and interest to implement novel risk prediction tools in bicuspid aortic valve-associated proximal aortic disease, so-called bicuspid aortic valve aortopathy. Inherent limitations of the diameter-based risk stratification for adverse aortic events in bicuspid aortic valve aortopathy patients have recently been recognized. Therefore, alternative diagnostic tools and subsequent adjustments in the treatment guidelines are urgently needed. Herein, we summarize the current evidence on recent diagnostic developments to improve risk stratification in bicuspid aortic valve aortopathy, including circulating microRNAs as biomarkers to predict the progression of aortic disease.
No takes yet. Share an insight, caveat, or question.
Naito et al. (2020) conducted a review in Bicuspid aortic valve aortopathy. Circulating microRNAs vs. Aortic diameter was evaluated on Progression of aortic disease. Circulating microRNAs are emerging as potential biomarkers to improve risk stratification and predict the progression of aortic disease in patients with bicuspid aortic valve aortopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: